Re:NewCell Valuation

Is RENEW undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RENEW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RENEW's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RENEW's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RENEW?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for RENEW. This is calculated by dividing RENEW's market cap by their current preferred multiple.
What is RENEW's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	SEK 219.03m

RENEW key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.1x
Enterprise Value/EBITDA	-4.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does RENEW's PS Ratio compare to its peers?

The above table shows the PS ratio for RENEW vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.4x
CIRCHE CirChem	9.2x	n/a	SEK 82.2m
NEXAM Nexam Chemical Holding	1.4x	15.1%	SEK 267.0m
ECO B EcoRub	2.8x	n/a	SEK 40.0m
DURC B Duroc	0.2x	n/a	SEK 704.0m
RENEW Re:NewCell	1.1x	83.0%	SEK 219.0m

Price-To-Sales vs Peers: RENEW is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (8.7x).

Price to Earnings Ratio vs Industry

How does RENEW's PE Ratio compare vs other companies in the European Chemicals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	10.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	10.1%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: RENEW is good value based on its Price-To-Sales Ratio (1.1x) compared to the European Chemicals industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is RENEW's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RENEW PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.1x
Fair PS Ratio	1.1x

Price-To-Sales vs Fair Ratio: RENEW is good value based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RENEW forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	n/a	SEK 40.00 0%	75.0%	SEK 70.00	SEK 10.00	n/a	2
Jun ’25	n/a	SEK 40.00 0%	75.0%	SEK 70.00	SEK 10.00	n/a	2
May ’25	n/a	SEK 40.00 0%	75.0%	SEK 70.00	SEK 10.00	n/a	2
Apr ’25	n/a	SEK 40.00 0%	75.0%	SEK 70.00	SEK 10.00	n/a	2
Mar ’25	SEK 5.30	SEK 40.00 +654.7%	75.0%	SEK 70.00	SEK 10.00	n/a	2
Feb ’25	SEK 8.88	SEK 40.00 +350.5%	75.0%	SEK 70.00	SEK 10.00	n/a	2
Jan ’25	SEK 7.61	SEK 40.00 +426.0%	75.0%	SEK 70.00	SEK 10.00	n/a	2
Dec ’24	SEK 7.57	SEK 40.00 +428.4%	75.0%	SEK 70.00	SEK 10.00	n/a	2
Nov ’24	SEK 10.92	SEK 81.00 +641.8%	81.5%	SEK 147.00	SEK 15.00	n/a	2
Oct ’24	SEK 67.90	SEK 166.33 +145.0%	14.4%	SEK 200.00	SEK 147.00	n/a	3
Sep ’24	SEK 86.60	SEK 166.33 +92.1%	14.4%	SEK 200.00	SEK 147.00	n/a	3
Aug ’24	SEK 79.65	SEK 206.33 +159.1%	24.8%	SEK 272.00	SEK 147.00	n/a	3
Jul ’24	SEK 80.20	SEK 197.67 +146.5%	31.2%	SEK 272.00	SEK 121.00	n/a	3
Jun ’24	SEK 76.70	SEK 197.67 +157.7%	31.2%	SEK 272.00	SEK 121.00	n/a	3
May ’24	SEK 80.35	SEK 203.67 +153.5%	34.7%	SEK 292.00	SEK 119.00	n/a	3
Apr ’24	SEK 81.30	SEK 224.00 +175.5%	30.6%	SEK 292.00	SEK 130.00	n/a	3
Mar ’24	SEK 92.00	SEK 224.00 +143.5%	30.6%	SEK 292.00	SEK 130.00	SEK 5.30	3
Feb ’24	SEK 95.35	SEK 181.00 +89.8%	38.1%	SEK 250.00	SEK 112.00	SEK 8.88	2
Jan ’24	SEK 72.90	SEK 181.00 +148.3%	38.1%	SEK 250.00	SEK 112.00	SEK 7.61	2
Oct ’23	SEK 72.00	SEK 275.00 +281.9%	9.1%	SEK 300.00	SEK 250.00	SEK 67.90	2
Sep ’23	SEK 89.30	SEK 275.00 +208.0%	9.1%	SEK 300.00	SEK 250.00	SEK 86.60	2
Aug ’23	SEK 100.30	SEK 275.00 +174.2%	9.1%	SEK 300.00	SEK 250.00	SEK 79.65	2
Jul ’23	SEK 95.95	SEK 275.00 +186.6%	9.1%	SEK 300.00	SEK 250.00	SEK 80.20	2
Jun ’23	SEK 118.10	SEK 275.00 +132.9%	9.1%	SEK 300.00	SEK 250.00	SEK 76.70	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.